Clinical trials: Sitagliptin
Diabetes Mellitus, Type 2
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin and placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (i.e.…
- Trial name
- NCT01106677
- Testing
- Canagliflozin, Sitagliptin, Metformin immediate release
- Where
- 125 sites in United States, Argentina and 20 more
- Volunteers
- 1,284 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes, Type 2
Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus
B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months.
- Trial name
- NCT01336738
- Testing
- 150 mg PF-04991532, 450 mg PF-04991532, 750 mg PF-04991532
- Where
- 44 sites in United States, Canada and 5 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)
This is a study comparing the incidence of hypoglycemia while using sitagliptin treatment versus sulfonylurea (SU) treatment in participants with type 2 diabetes mellitus (T2DM) who regularly take an SU drug, and choose to fast…
- Trial name
- NCT01340768
- Testing
- Sitagliptin, Sulfonylurea, Metformin
- Volunteers
- 870 people
- Sponsor
- Merck Sharp & Dohme LLC
Bioequivalence, Type 2 Diabetes
Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers
The objective of this study was to determine the bioequivalence of two different formulations of sitagliptin/ metformin after a single oral dose administration under fed conditions.
- Trial name
- NCT05549583
- Testing
- Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
- Where
- Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Type II Diabetes
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.
- Trial name
- NCT01619332
- Testing
- Sitagliptin, LEZ763
- Where
- 6 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
This study will compare the effects of 2.0 mg exenatide once weekly injection as monotherapy to 3 active comparators(metformin, dipeptidyl peptidase-4 inhibitor, and thiazolidinedione) in drug naive patients with type 2 diabetes…
- Trial name
- NCT00676338
- Testing
- exenatide once weekly, metformin, sitagliptin
- Where
- 106 sites in United States, Argentina and 20 more
- Volunteers
- 820 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients
The primary objective was to demonstrate the superiority of insulin glargine over sitagliptin in reducing Glycosylated Hemoglobin A1c (HbA1c) from baseline to the end of the treatment period.
- Trial name
- EASIE (NCT00751114)
- Testing
- Insulin Glargine, Sitagliptin, Metformin
- Where
- 17 sites in United States, Austria and 15 more
- Volunteers
- 515 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)
This study will compare the benefits of exenatide once weekly treatment to those achieved by the approved antidiabetic therapies sitagliptin and pioglitazone in subjects whose type 2 diabetes is managed with metformin therapy…
- Trial name
- NCT00637273
- Testing
- exenatide once weekly, sitagliptin, pioglitazone
- Where
- 62 sites in United States, India and 1 more
- Volunteers
- 514 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Non-Insulin-Dependent
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.
- Trial name
- NCT00411554
- Testing
- sitagliptin phosphate, Comparator: voglibose
- Volunteers
- 319 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers
Crossover study to compare the pharmacokinetic characteristics of GLH1SM sustained release tablet and Janumet XR tablet in fasting condition
- Trial name
- NCT03851341
- Testing
- Janumet XR tablet 100/1000 mg, GLH1SM tablet 100/1000 mg
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GL Pharm Tech Corporation
Type 2 Diabetes Mellitus
A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)
This study will assess the effects of sitagliptin and metformin alone and after co-administration on incretin hormone concentrations in patients with Type 2 diabetes.
- Trial name
- NCT00830076
- Testing
- sitagliptin phosphate, metformin hydrochloride
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus Non-insulin-dependent
The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)
to assess the effect of treatment with Sitagliptin (MK0431) on HbA1c (Hemoglobin A1c) and the safety and tolerability of Sitagliptin.
- Trial name
- NCT00832624
- Testing
- sitagliptin
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Subjects
A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of SID1903 and SID1903-R1/SID1903-R2 in healthy adult volunteers.
- Trial name
- NCT05236998
- Testing
- SID1903 (FDC), Dapagliflozin and Sitagliptin
- Where
- South Korea
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate…
- Trial name
- LIRA-SWITCH™ (NCT01907854)
- Testing
- liraglutide, sitagliptin
- Where
- 106 sites in United States, Canada and 5 more
- Volunteers
- 407 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
This study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and sitagliptin (a medicine doctors can already prescribe).
- Trial name
- PIONEER 12 (NCT04017832)
- Testing
- Oral semaglutide, Sitagliptin
- Where
- 93 sites in Algeria, Brazil and 7 more
- Volunteers
- 1,441 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
- Trial name
- PIONEER 3 (NCT02607865)
- Testing
- semaglutide, sitagliptin
- Where
- 242 sites in United States, Argentina and 13 more
- Volunteers
- 1,864 people
- Sponsor
- Novo Nordisk A/S
Type2 Diabetes Mellitus
Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
The purpose of this study is to examine the drug-drug interaction in your body when given the study drug, bexagliflozin, with three commonly used ant-diabetic medications, metformin, glimepiride or sitagliptin.
- Trial name
- NCT02956044
- Testing
- Bexagliflozin, Metformin, Glimepiride
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Theracos
Dyslipidaemias
A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.
This study is the first study in humans to assess the safety and tolerability of various doses of GSK1292263 alone, and taken with sitigliptan.
- Trial name
- NCT00783549
- Testing
- an undetermined dose of GSK1292263, ascending dose of GSK1292263
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Subjects
A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of SID1903 and SID1903-R1/SID1903-R2 in healthy adult volunteers.
- Trial name
- NCT05453786
- Testing
- SID1903, SID1903-R1/SID1903-R2
- Where
- South Korea
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Type 2 Diabetes
Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 Add-on to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin…
- Trial name
- NCT07076056
- Testing
- DW1026C1, DW1026C2, DW1026S
- Where
- South Korea
- Volunteers
- 230 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.